Company intelligence / Profile preview

Cohen Global

London, England, United Kingdom

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Cohen Global is developing MD-18, a synthetic peptide targeting PTP1B for the treatment of obesity and diabetes. Phase 1 clinical trials have been initiated to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy adults and overweight/obese subjects. As of 2025, clinical development is ongoing with no reported pivotal efficacy results.

Therapeutic areas: Endocrinology
Modalities: Synthetic peptide
Industry: Biotech

Beyond the preview

Go deeper on Cohen Global.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cohen Global.

Explore the full profile